Related Experiment Video
Updated: Aug 5, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Pharmacogenetics in cardiovascular antithrombotic therapy
Francisco Marín1, Vanessa Roldán, Rocío González-Conejero
1Cardiology Department, Hospital General Universitario, C/ Pintor Baeza s/n, Alicante, Spain. fcomarino@hotmail.com
Insights
Genetic variations influence how individuals respond to antithrombotic drugs, impacting treatment efficacy for thrombosis and cardiovascular diseases. Understanding these pharmacogenetic factors is key to improving patient outcomes.
Area of Science:
- Cardiovascular Medicine
- Pharmacogenetics
- Genetics
Background:
- Thrombosis is a primary cause of coronary heart disease and stroke, necessitating antithrombotic therapy.
- Current antithrombotic treatments show limited clinical benefits due to significant inter-individual heterogeneity in patient response.
- Identifying factors contributing to this heterogeneity is crucial for optimizing therapeutic strategies.
Purpose of the Study:
- To explore the influence of genetic factors on the efficacy of antithrombotic drugs.
- To analyze how specific genetic polymorphisms modulate individual responses to commonly used antithrombotic medications.
Main Methods:
- Review of existing literature on pharmacogenetics and antithrombotic therapy.
- Analysis of genetic polymorphisms affecting drug disposition, metabolism, transporters, and targets.
- Examination of the impact of these polymorphisms on drug efficacy and side effects.
Main Results:
- Genetic polymorphisms significantly contribute to inter-individual variability in response to antithrombotic agents.
- Specific gene variants can alter drug metabolism, target interaction, and overall treatment effectiveness.
- Understanding these genetic influences can help predict patient response and tailor antithrombotic therapy.
Conclusions:
- Pharmacogenetics offers a promising avenue for personalizing antithrombotic treatment strategies.
- Identifying genetic markers can help mitigate treatment failures and adverse events associated with antithrombotic drugs.
- Further research into genetic influences is essential for improving the clinical application of antithrombotic therapies.
Abstract:
Thrombosis is the most important underlying mechanism of coronary heart disease and embolic stroke. Therefore, antithrombotic therapy is commonly used in cardiovascular diseases. Unfortunately, the benefits are limited, and an important proportion of treated patients will suffer a new thrombotic event. Lack of clinical benefits may be related to heterogeneous response to antithrombotic treatment among individuals (inter-individual heterogeneity). Few factors have been identified to be involved in this inter-individual heterogeneity. Recently, pharmacogenetic has emerged as a new field in medicine that tries to identify gene variants able to explain the heterogeneity in patient's response to a drug. Polymorphisms affecting disposition, metabolism, transporters or targets of the drug could modify the individual response to one therapy, and probably its side effects. The present review article explores the genetic influence on antithrombotic drug efficacy, analysing the modulating role of different polymorphisms on individuals' response to drugs commonly used in current day practice.
Related Concept Videos
Pharmacogenetics and Pharmacogenomics: Overview
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets

